UCB SA (LON:0NZT)

Market Cap	28.52B
Revenue (ttm)	4.62B
Net Income (ttm)	203.48M
Shares Out	n/a
EPS (ttm)	1.04
PE Ratio	140.14
Forward PE	n/a
Dividend	0.82 (0.45%)
Ex-Dividend Date	Apr 26, 2024

Volume	7,843
Average Volume	111,547
Open	178.10
Previous Close	179.64
Day's Range	177.55 - 181.55
52-Week Range	62.75 - 157.38
Beta	0.33
RSI	36.58
Earnings Date	Feb 27, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 9,083
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZT

Financial Performance

In 2023, UCB SA's revenue was 5.18 billion, a decrease of -4.87% compared to the previous year's 5.45 billion. Earnings were 343.00 million, a decrease of -17.94%.

Financial numbers in EUR